Skip to Content

H. Lundbeck AS Ordinary Shares - Class B HLUN B

Morningstar Rating
DKK 37.40 +0.16 (0.43%)
View Full Chart
Unlock our analysis with Morningstar Investor

Price vs Fair Value

HLUN B is trading at a 873% premium.
Price
DKK 37.40
Fair Value
DKK 42.50
Uncertainty
High
1-Star Price
DKK 33.75
5-Star Price
DKK 91.50
Economic Moat
Dyxj
Capital Allocation
Rzqzwhzwx
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HLUN B is a good fit for your portfolio.

Trading Information

Previous Close Price
DKK 37.24
Day Range
DKK 37.1037.86
52-Week Range
DKK 30.9639.84
Bid/Ask
DKK 37.26 / DKK 37.30
Market Cap
DKK 37.10 Bil
Volume/Avg
652,440 / 544,298

Key Statistics

Price/Earnings (Normalized)
7.83
Price/Sales
1.84
Dividend Yield (Trailing)
1.87%
Dividend Yield (Forward)
1.87%
Total Yield
1.99%

Company Profile

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
5,700

Competitors

Valuation

Metric
HLUN B
ALNY
EXEL
Price/Earnings (Normalized)
7.8321.01
Price/Book Value
1.652.90
Price/Sales
1.849.353.58
Price/Cash Flow
7.2587.7519.31
Price/Earnings
HLUN B
ALNY
EXEL

Financial Strength

Metric
HLUN B
ALNY
EXEL
Quick Ratio
1.082.863.23
Current Ratio
1.663.083.46
Interest Coverage
54.83−3.36
Quick Ratio
HLUN B
ALNY
EXEL

Profitability

Metric
HLUN B
ALNY
EXEL
Return on Assets (Normalized)
11.24%−2.47%9.61%
Return on Equity (Normalized)
19.46%12.20%
Return on Invested Capital (Normalized)
15.82%−7.00%8.59%
Return on Assets
HLUN B
ALNY
EXEL
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ALnmwbcmfpMhqj$79.4 Bil
MKKGY
Merck KGaA ADRXbyxjlwtfMgzjfj$79.0 Bil
HLN
Haleon PLC ADRSxpvkhyfrGsq$38.5 Bil
VTRS
Viatris IncVqbcrxrqRjlf$13.1 Bil
RDY
Dr Reddy's Laboratories Ltd ADRVygbbjmVmg$11.7 Bil
CTLT
Catalent IncKblbypcxWbqldcx$10.0 Bil
CURLF
Curaleaf Holdings IncFlbqkkhXlfg$4.2 Bil
PRGO
Perrigo Co PLCLgkwqkqkhJzkwf$4.1 Bil
PBH
Prestige Consumer Healthcare IncTtzjwqbMdtkx$3.2 Bil
GTBIF
Green Thumb Industries IncZyhtvlpqwTznrl$3.1 Bil

Sponsor Center